Protocol Ledger

NCT03822117 · Phase II · TERMINATED

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Interventional Phase II clinical trial protocol NCT03822117 sponsored by Incyte in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-17 Enrollment: 111 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03822117
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)111 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03822117
Protocol FieldVerified Registry Value
NCT IdentifierNCT03822117
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment111 participants (ACTUAL)
Registered Start Date2019-10-17
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI